ArticleJournal of managed care & specialty pharmacy2026
Comparing rates of primary medication nonadherence and turnaround time among patients at a health system specialty pharmacy compared with external specialty pharmacies.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccess to specialty medications prescribed for complex and debilitating conditions is often delayed or unsuccessful. Specialty pharmacies can streamline medication access and timely delivery.
objectiveTo compare primary medication nonadherence (PMN), the rate at which a prescription is written but not obtained by the patient, and turnaround time (TAT) between patients filling specialty medication with an integrated health system specialty pharmacy (HSSP) and those using external specialty pharmacies (non-HSSP).
methodsA retrospective single-center cohort study was performed between June 2021 and May 2022. Patients prescribed specialty medications from the Vanderbilt Health System Oncology, Inflammatory, or Multiple Sclerosis clinics were included if they had a new prescription within the study period and follow-up encounter after the prescription. The primary outcome was PMN, defined as the prescribed medication or therapeutic alternative confirmed to not be filled. TAT was defined as time from a specialty medication prescription to the first filled claim. A logistic regression model was used to test for associations with PMN and the pharmacy the medication was sent to (HSSP vs non-HSSP), controlling for age, sex, clinic, race, and insurance. An ordinal logistic regression model was used to test for associations with TAT and the filling pharmacy (HSSP vs non-HSSP), controlling for age, sex, clinic, race, and insurance.
resultsThere were 1,466 patients with 1 eligible prescription (67% HSSP and 33% non-HSSP) evaluated for PMN. Of these patients, the median age was 56 (interquartile range [IQR] 41-68) years, 55% of patients were female, and 56% had commercial insurance. PMN was 6.5% for HSSP patients, and 9.9% for non-HSSP patients. Patients who had a prescription sent to non-HSSP pharmacies had 60% higher odds of having PMN (
conclusionsPrescriptions sent to non-HSSP specialty pharmacies are more likely to not be filled or to take longer to fill than those sent to an HSSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.